Cyclerion Therapeutics (CYCN) Appoints Steven E. Hyman to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
July 26, 2022 7:00 AM EDTCAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E. Hyman, M.D., to its Board of Directors effective July 25. Dr. Hyman will work with Cyclerion leadership to help shape the future of its research and clinical development strategy while expanding external collaborations with scientific leaders and industry partners.
We are delighted to welcome Dr. Steve Hyman to Cyclerion. Steve is a world-renowned leader in neuroscience with deep expertise leading... More
